<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35272595</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5453</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Current drug metabolism</Title><ISOAbbreviation>Curr Drug Metab</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Approaches to Amyotrophic Lateral Sclerosis from the Lab to the Clinic.</ArticleTitle><Pagination><StartPage>200</StartPage><EndPage>222</EndPage><MedlinePgn>200-222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1389200223666220310113110</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a terminal neuro-degenerative disorder that is clinically recognized as a gradual degeneration of the upper and lower motor neurons, with an average duration of 3 to 5 years from initial of symptoms to death. The mechanisms underlying the pathogenesis and progression of the disease are multifactorial. Therefore, to find effective treatments, it is necessary to understand the heterogeneity underlying the progression of ALS. Recent developments in gene therapy have opened a new avenue to treat this condition, especially for the characterized genetic types. Gene therapy methods have been studied in various pre-clinical settings and clinical trials, and they may be a promising path for developing an effective and safe ALS cure. A growing body of evidence demonstrates abnormalities in metabolic energy at the cellular and whole-body level in animal models and people living with ALS. Using and incorporatig high-throughput "omics" methods have radically transformed our thoughts about ALS, strengthened our understanding of the disease's dynamic molecular architecture, differentiated distinct patient subtypes, and created a reasonable basis for identifying biomarkers and novel individualised treatments. Future clinical and laboratory trials would also focus on the diverse relationships between metabolism and ALS to address the issue of whether targeting poor metabolism in ALS is an effective way to change disease progression. In this review, we focus on the detailed pathogenesis of ALS and highlight principal genes, i.e., SOD1, TDP-43, C9orf72, and FUS, as well as targeted ALS therapies. An attempt is made to provide up-to-date clinical outcomes, including various biomarkers that are thought to be important players in early ALS detection.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chavda</LastName><ForeName>Vivek P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutic and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad - 380009, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Chirag</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, LM College of Pharmacy, Ahmedabad - 380009, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modh</LastName><ForeName>Dharti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharti Vidhyapith, Pune - 411030, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertas</LastName><ForeName>Yavuz Nuri</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering at Erciyes University, Kayseri, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ERNAM - Nanotechnology Research and Application Center, Erciyes University, Kayseri 38039, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonak</LastName><ForeName>Shreya S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharti Vidhyapith, Pune - 411030, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munshi</LastName><ForeName>Nafesa K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharti Vidhyapith, Pune - 411030, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Krishnan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein 9300, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soni</LastName><ForeName>Arun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, SSR College of Pharmacy, Silvassa, Dadra and Nagar Haveli - 396230, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pande</LastName><ForeName>Sonal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research and Development, Meril Diagnostic Pvt. Ltd, Vapi - 396191, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>118C346</GrantID><Agency>T&#xdc;B&#x130;TAK</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Drug Metab</MedlineTA><NlmUniqueID>100960533</NlmUniqueID><ISSNLinking>1389-2002</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35272595</ArticleId><ArticleId IdType="doi">10.2174/1389200223666220310113110</ArticleId><ArticleId IdType="pii">CDM-EPUB-121494</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>